Core Viewpoint - Lijun Pharmaceutical Group has received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) [1] Group 1: Product Information - JP-1366 tablets work by competitively blocking the K(+) channel of the H(+), K(+)-ATPase (proton pump), inhibiting the binding of K(+) to the proton pump, thereby suppressing gastric acid secretion [1] - The product promotes esophageal mucosal healing and improves reflux symptoms, with a rapid increase in gastric pH and the ability to maintain gastric pH above 4 for an extended period, effectively addressing nighttime acid breakthrough [1] Group 2: Financial Investment - As of the announcement date, the total research and development expenses directly invested in JP-1366 tablets amount to approximately RMB 185.21 million [1]

Core Viewpoint - Health元's subsidiary, Lijun Pharmaceutical Group, has received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) [1] Group 1 - JP-1366 tablets work by competitively blocking the K(+) channel of H(+), K(+)-ATPase (proton pump), inhibiting the binding of K(+) to the proton pump, and suppressing gastric acid secretion [1] - The drug promotes esophageal mucosal healing and improves reflux symptoms [1] - JP-1366 tablets can rapidly increase gastric pH levels and maintain gastric pH above 4 for an extended period, effectively addressing nighttime acid breakthrough [1]